Biotech Values

[mcbio]

Triple damages if you launch at risk and lose at court.

So it is a real risk, and given NVS's size, not one worth taking unless it is pretty clear cut they are going to win at trial.

Ouch, ok thanks Tinker. Yeah, that's pretty steep so I wouldn't imagine an at-risk launch either given the amount of revenues we would be talking about for a generic Copaxone.